FIGO分级在错配修复缺陷型子宫内膜癌中无预后价值
该研究 pooled 三项随机试验(PORTEC-1/2/3)和五个临床队列共3158例子宫内膜癌,其中2621例完成分子分型,730例(27.9%)为MMRd。在MMRd亚组中,低级别与高级别肿瘤的5年复发累积发生率(18.0% vs 18.8%,p=0.67)和癌症特异性死亡累积发生率(12.3% vs 14.2%,p=0.44)均无差异,多变量分析显示FIGO分级与复发(HR 0.83,95%CI 0.56-1.24;p=0.37)和癌症特异性死亡(HR 0.97,95%CI 0.62-1.51;p=0.89)均无独立关联。结论认为MMRd子宫内膜癌中FIGO分级无预后作用,可省略于风险分层和辅助治疗决策。
要点
- MMRd子宫内膜癌中低级别与高级别肿瘤的5年复发和癌症特异性死亡累积发生率无显著差异。
- 校正年龄、分期、组织学类型、LVSI和辅助治疗后,FIGO分级与复发和癌症特异性死亡均无独立关联。
- MMRd子宫内膜癌的风险分层和辅助治疗决策可考虑省略FIGO分级。
核心结论
- FIGO分级在MMRd子宫内膜癌中无预后价值,可省略于风险分层和辅助治疗决策。
研究设计与样本
- 汇总三项随机试验(PORTEC-1 n=714;PORTEC-2 n=427;PORTEC-3 n=660)和五个临床队列(n=1357)的数据,纳入I-III期子宫内膜样和非子宫内膜样子宫内膜癌患者。
- 肿瘤按2020 WHO诊断算法进行分子分型,并由专家妇科病理学家进行中心病理复核。
- 采用Aalen-Johansen法估计病因特异性累积发生率,Gray检验比较;采用多变量病因特异性Cox回归模型评估FIGO分级的独立预后价值。
主要发现
- 3158例子宫内膜癌中2621例(83.0%)完成分子分型,其中MMRd肿瘤730例(27.9%):低级别405例(55.5%),高级别325例(44.5%)。
- 中位随访7.2年,低级别与高级别MMRd子宫内膜癌的5年总体复发累积发生率分别为18.0%和18.8%(p=0.67),癌症特异性死亡累积发生率分别为12.3%和14.2%(p=0.44)。
- 多变量分析校正年龄、分期、组织学类型、LVSI和辅助治疗后,FIGO分级与总体复发(HR 0.83 [95%CI 0.56-1.24];p=0.37)和癌症特异性死亡(HR 0.97 [0.62-1.51];p=0.89)均无独立关联。
临床怎么用
- 在MMRd子宫内膜癌的风险分层和辅助治疗决策中,可考虑省略FIGO分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prognostic value of FIGO grading in endometrial cancer (EC) varies across molecular subgroups: it is no longer considered relevant in POLEmut and p53abn tumours, but remains prognostic in NSMP tumours. Its relevance is unclear in mismatch repair deficient (MMRd) EC. Using a large collection of molecularly classified EC, this study evaluated the prognostic role of FIGO grading in MMRd EC. METHODS: Data from three randomised trials (PORTEC-1 (n = 714); PORTEC-2 (n = 427); PORTEC-3 (n = 660)) and five clinical cohorts (n = 1357) were pooled, yielding patients with stage I-III endometrioid and non-endometrioid EC. Tumours were molecularly classified according to the 2020 WHO diagnostic algorithm, with central pathology review by an expert gynaecopathologist. Cause-specific cumulative incidence was estimated using the Aalen-Johansen method and compared using Gray's test. The independent prognostic value of FIGO grading was assessed using multivariable cause-specific Cox regression models. RESULTS: In total, 2621 (83.0%) of the 3158 EC cases were molecularly classified, including 730 (27.9%) MMRd tumours: 405 (55.5%) were low-grade and 325 (44.5%) were high-grade. Median follow-up was 7.2 years. Five-year cumulative incidence of overall recurrence (18.0% vs. 18.8%, p = 0.67) and cancer-specific death (12.3% vs. 14.2%; p = 0.44) did not differ between low- and high-grade MMRd EC. In multivariable analyses, corrected for age, stage, histotype, LVSI and adjuvant treatment, FIGO grading was not independently associated with overall recurrence (HR 0.83 [95%CI 0.56-1.24]; p = 0.37) or cancer-specific death (HR 0.97 [0.62-1.51]; p = 0.89). CONCLUSION: In conclusion, FIGO grading has no prognostic role in MMRd EC and may be omitted in risk stratification and adjuvant treatment decisions.
引用
- Wakkerman FC, Post CCB, Ørtoft G, et al. No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma. Eur J Cancer. 2026. PMID: 42320406. doi:10.1016/j.ejca.2026.116885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。